SUPN
SupernusBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case assumes successful commercial momentum and positive analyst re-rating toward the high end of consensus, validating premium multiple and driving price toward the analyst high.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +13.7.
What can break
Analyst downgrades or consensus target compression
Momentum
29
Value
60
Sentiment
88
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $61.50 · Bull $68.25 · Bear $51.35
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-25 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $63.17
Why
Momentum29 · Δ7d -12.3
Value60 · Δ7d +0.8
Sentiment88 · Δ7d +13.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
29
34% active weight
Current posture
7d trendSoftening
Δ7d
-12.3
Δ21d
+2.9
Value
60
32% active weight
Current posture
7d trendFlat
Δ7d
+0.8
Δ21d
+1.2
Sentiment
88
33% active weight
Current posture
7d trendImproving
Δ7d
+13.7
Δ21d
+22.4
Why this grade
Composite grade B. Momentum 29.4 / Value 60.1 / Sentiment 88.2
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$2.56B
Beta
0.71
Shares Out
57.34M
P/E (TTM)
49.8
P/S (TTM)
4.16
P/FCF (TTM)
40.04
Rev YoY
+9.3%
EPS YoY
-216.1%
Gross Margin
+89.9%
Op Margin
-5.4%
Net Debt
-
Current Ratio
1.80
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology